AngioDynamics, Inc. — Form 10-Q Summary
Business context and reporting period. The company designs and sells medical devices for vascular and oncology/surgical procedures. This unaudited report covers the fiscal third quarter and first nine months ended February 29, 2012; comparisons are with the periods ended February 28, 2011. Amounts below are in millions unless noted.
Financial performance and liquidity
| Metric | Q3 FY2012 | Q3 FY2011 | Nine months FY2012 | Nine months FY2011 |
|---|---|---|---|---|
| Net sales | $51.6 | $54.6 | $164.1 | $159.5 |
| Gross profit / margin | $29.4 / 57.0% | $31.7 / 58.0% | $94.8 / 57.8% | $93.3 / 58.5% |
| Operating income (loss) | $(2.8) | $5.2 | $3.9 | $14.1 |
| Net income (loss) | $(1.8) | $3.8 | $1.9 | $9.0 |
| Diluted earnings (loss) per share | $(0.07) | $0.15 | $0.08 | $0.36 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $12.5 | $22.0 |
- Q3 sales declined 5.6%; nine-month sales increased 2.9%. Q3 operating margin was -5.3%, versus 9.6%; the nine-month margin was 2.4%, versus 8.9%.
- At February 29, cash and cash equivalents were $34.0 and marketable securities were $109.0, totaling $143.0, up from $131.5 at May 31, 2011. Total debt was $6.3, down from $6.6; total liabilities were $35.2 and stockholders’ equity was $411.4.
- Nine-month cash from operations was $12.5; investing used $25.4, primarily for net marketable-security purchases, and financing provided $1.0. Cash and cash equivalents decreased $11.9 to $34.0.
- Management said existing cash and investments plus operating cash generation should meet anticipated capital needs for at least 12 months. The filing does not provide formal earnings or revenue guidance.
Material changes and operating drivers
- Q3 Vascular sales were $37.9, down 1%; Oncology/Surgery sales were $13.7, down 16%. For nine months, Vascular sales rose 1% to $112.8 and Oncology/Surgery rose 7% to $51.3.
- Q3 sales fell primarily because LC Bead sales declined $2.6 after the U.S. distribution agreement expired on December 31, 2011. LC Bead sales were $4.2 in Q3 versus $6.7 a year earlier; nine-month sales were $21.3 versus $20.0.
- International sales increased 26% to $7.9 in Q3 and 24% to $23.5 for nine months. U.S. sales fell 10% to $43.6 in Q3 and were essentially flat at $140.6 for nine months.
- Margins were pressured by lower average selling prices, quality-program spending and voluntary product recalls; material-cost reductions and improved factory utilization partly offset those effects. Sales and marketing expense increased 9% in Q3 and 12% year to date, while R&D expense decreased 14% and 3%, respectively.
- Q3 acquisition, restructuring and other costs were $5.0, including $3.8 related to the proposed Navilyst acquisition. Nine-month costs were $7.4, including UK facility closure and executive-transition costs. The filing also reports $912,000 of direct Quality Call to Action Program expense in Q3 and recall-related costs of $438,000 in Q3 and $1.9 for nine months.
Outlook, significant developments and risks
- Navilyst acquisition: In January 2012, AngioDynamics agreed to acquire Navilyst in a cash-and-stock transaction valued at approximately $372 million. The company anticipated a May 2012 closing, subject to shareholder approval, antitrust clearance and customary conditions. Planned financing included approximately $97 million of cash and $150 million of new debt, along with stock issuance; approximately 9.5 million shares were expected to be issued. Management estimated post-close liquidity of $50 million, debt of $150 million and a $50 million revolving facility.
- Microsulis relationship: In March 2012, the company invested $5 million for a 14.3% preferred-stock interest, obtained exclusive distribution rights outside the U.S. through December 2013, and received an option to acquire substantially all global assets through September 2013.
- FDA matters: The company received Forms 483 after inspections of its Queensbury and Fremont facilities, listing 12 and 6 observations, respectively, including repeat quality-system and reporting issues. It reported responses to the FDA and a comprehensive quality initiative. Further regulatory action—including restrictions, recall, fines or injunction—could materially affect operations and results.
- Litigation: C.R. Bard sued over alleged patent infringement by certain implantable ports; AngioDynamics disputes the claims. In its separate biolitec litigation, the company obtained a favorable summary-judgment ruling on key issues but had not recorded a gain, as damages remained uncertain and no judgment amount had been entered.
- Other exposures: Two failed-auction municipal securities totaling $1.85 million remained illiquid, though issuers were current on interest. Goodwill was not impaired at December 31, 2011, but the Vascular reporting unit’s fair value exceeded carrying value by only 6%; a 1% increase in its discount rate would have reduced fair value below carrying value, according to the filing.
Important facts for investors to verify
- Whether the Navilyst transaction closed on schedule and its final purchase price, financing, share issuance, integration costs and effect on leverage and liquidity.
- Progress in resolving FDA observations and whether additional regulatory measures, recalls or quality costs arise.
- Sales and margin trends after the LC Bead distribution agreement expired, including pricing, segment performance and international growth.
- Actual cash generation and liquidity needs, including the Microsulis investment and any acquisition-related borrowing.
- Developments in the Bard and biolitec litigation, and any change in goodwill impairment assumptions or headroom.